Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 6840432, 8 pages
http://dx.doi.org/10.1155/2016/6840432
Research Article

Traditional Chinese Medicine Huannao Yicong Decoction Extract Decreases Tau Hyperphosphorylation in the Brain of Alzheimer’s Disease Model Rats Induced by Aβ1–42

Institute of Geriatrics, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

Received 22 July 2016; Revised 26 September 2016; Accepted 30 October 2016

Academic Editor: Genevieve Steiner

Copyright © 2016 Yu Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Solanki, P. Parihar, and M. S. Parihar, “Neurodegenerative diseases: from available treatments to prospective herbal therapy,” Neurochemistry International, vol. 95, pp. 100–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Morris, S. Maeda, K. Vossel, and L. Mucke, “The many faces of tau,” Neuron, vol. 70, no. 3, pp. 410–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Majd, J. H. Power, and H. J. M. Grantham, “Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways,” BMC Neuroscience, vol. 16, no. 1, article 69, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Li, M.-F. Liu, J.-G. Liu et al., “Effect of Huannao Yicong prescription (还脑益聪方) extract on β-amyloid precursor protein metabolic signal transduction-related protein in brain tissue of dementia model transgenic mouse,” Chinese Journal of Integrative Medicine, vol. 18, pp. 683–689, 2012. View at Google Scholar
  5. H. Li, M.-J. Yao, W.-M. Zhao, J. Guan, L.-L. Cai, and L. Cui, “A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment,” Journal of Chinese Integrative Medicine, vol. 6, no. 1, pp. 25–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. J. Hernández-Pérez, B. E. Gutiérrez-Guzmán, M. Á. López-Vázquez, and M. E. Olvera-Cortés, “Supramammillary serotonin reduction alters place learning and concomitant hippocampal, septal, and supramammillar theta activity in a Morris water maze,” Frontiers in Pharmacology, vol. 6, article 250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. J. H. Sloan, B. J. Ackermann, M. O'Dell, R. R. Bowsher, R. A. Dean, and R. J. Konrad, “Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibody,” Journal of Pharmaceutical and Biomedical Analysis, vol. 56, no. 5, pp. 1029–1034, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Jayant, B. M. Sharma, R. Bansal, and B. Sharma, “Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer's disease,” Pharmacology Biochemistry and Behavior, vol. 140, pp. 39–50, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. D. P. Devanand, S. Lee, J. Manly et al., “Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community,” Neurology, vol. 84, no. 2, pp. 182–189, 2014. View at Google Scholar · View at Scopus
  11. S. Oddo, L. Billings, J. P. Kesslak, D. H. Cribbs, and F. M. LaFerla, “Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome,” Neuron, vol. 43, no. 3, pp. 321–332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Sui, X. Xu, X. Ye et al., “Protein interaction module-assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5/p25 kinase complex,” Molecular and Cellular Proteomics, vol. 14, no. 1, pp. 251–262, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Gąssowska, G. A. Czapski, B. Pajaķ, M. Ciesĺik, A. M. Lenkiewicz, and A. Adamczyk, “Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent Tau phosphorylation in PC12 cells,” PLoS ONE, vol. 9, no. 4, Article ID e94259, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Sofola, F. Kerr, I. Rogers et al., “Inhibition of GSK-3 ameliorates Aβ pathology in an adult-onset Drosophila model of Alzheimer's disease,” PLoS Genetics, vol. 6, no. 9, Article ID e1001087, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Gao, C. Hölscher, Y. Liu, and L. Li, “GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease,” Reviews in the Neurosciences, vol. 23, no. 1, pp. 1–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Lebel, C. Patenaude, J. Allyson, G. Massicotte, and M. Cyr, “Dopamine D1 receptor activation induces tau phosphorylation via cdk5 and GSK3 signaling pathways,” Neuropharmacology, vol. 57, no. 4, pp. 392–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Tokutake, K. Kasuga, R. Yajima et al., “Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway,” Journal of Biological Chemistry, vol. 287, no. 42, pp. 35222–35233, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Chabrier, M. Blurton-Jones, A. A. Agazaryan, J. L. Nerhus, H. Martinez-Coria, and F. M. LaFerla, “Soluble Aβ promotes wild-type tau pathology in vivo,” The Journal of Neuroscience, vol. 32, no. 48, pp. 17345–17350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Liu, H. Jin, Q.-R. Sun, J.-H. Xu, and H.-T. Hu, “Neuroprotective effects of emodin in rat cortical neurons against β-amyloid-induced neurotoxicity,” Brain Research, vol. 1347, pp. 149–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. X.-Y. Song, J.-F. Hu, S.-F. Chu et al., “Ginsenoside Rg1 attenuates okadaic acid induced spatial memory impairment by the GSK3β/tau signaling pathway and the Aβ formation prevention in rats,” European Journal of Pharmacology, vol. 710, no. 1–3, pp. 29–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Li, D.-E. Xu, and T. Ma, “Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons,” Neuroscience, vol. 294, pp. 14–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Vijayapandi, V. Annabathina, B. SivaNagaSrikanth et al., “In vitro anticholinergic and antihistaminic activities of Acorus calamus Linn. leaves extracts,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 10, no. 1, pp. 95–101, 2012. View at Google Scholar · View at Scopus
  23. F. Zhu and C. Qian, “Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1 beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease,” BMC Neuroscience, vol. 7, article 78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. S. S. K. Durairajan, L.-F. Liu, J.-H. Lu et al., “Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model,” Neurobiology of Aging, vol. 33, no. 12, pp. 2903–2919, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Oikawa, K. Ogino, T. Masumoto, H. Yamaguchi, and K. Yanagisawa, “Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-ceruleus-injured APP-transgenic mouse,” Neuroscience Letters, vol. 468, no. 3, pp. 243–247, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. X. Wong, Y. H. Hung, A. I. Bush, and J. A. Duce, “Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology,” Frontiers in Aging Neuroscience, vol. 6, article 91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Pamphlett and S. Kum Jew, “Different populations of human locus ceruleus neurons contain heavy metals or hyperphosphorylated Tau: implications for amyloid-β and tau pathology in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 45, no. 2, pp. 437–447, 2015. View at Publisher · View at Google Scholar · View at Scopus